Literature DB >> 8326458

An immunohistochemical study of the long-term effects of androgen administration on female-to-male transsexual breast: a comparison with normal female breast and male breast showing gynaecomastia.

H E Burgess1, S Shousha.   

Abstract

This study was aimed at assessing the effects of therapeutic long-term administration of androgens on normal human female breast. Sections from mastectomy specimens of 29 female-to-male transsexuals who had prolonged androgen administration prior to surgery were examined using routine light microscopy and immunohistochemical techniques. For comparison, sections from ten 'normal' female breast reduction mammoplasty specimens and ten cases of gynaecomastia were similarly examined. Haematoxylin and eosin-stained sections were assessed for the prevalence of elements of the normal breast and benign breast lesions. Immunoperoxidase techniques were performed to study the distribution of a variety of breast-associated antigens and receptors. The results were assessed semi-quantitatively. The prevalence of normal acini and ducts, fibrosis, cysts, and apocrine metaplasia in transsexual specimens was not statistically different from that seen in normal controls. However, transsexual specimens had a significantly higher prevalence of microcalcification than normals. The majority of transsexual specimens were positive for gross cystic disease fluid protein-15, lactoferrin, and progesterone and oestrogen receptors, and negative for B72.3 and pS2. These findings were not significantly different from those in normal controls. All ten gynaecomastia specimens were positive for oestrogen and progesterone receptors. The prevalence of oestrogen receptors was significantly higher than that seen in transsexuals and normal controls, but the prevalence of progesterone receptors was only significantly higher than that seen in transsexuals. It is concluded that long-term androgen administration does not appear to have any significant lasting effect on the normal human female breast, as demonstrated by a wide range of histological and immunohistological criteria.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8326458     DOI: 10.1002/path.1711700107

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  7 in total

Review 1.  Gynaecomastia--pathophysiology, diagnosis and treatment.

Authors:  Harmeet S Narula; Harold E Carlson
Journal:  Nat Rev Endocrinol       Date:  2014-08-12       Impact factor: 43.330

2.  The Role of Androgens in Normal and Malignant Breast Tissue.

Authors:  Katharina Tiefenbacher; Günter Daxenbichler
Journal:  Breast Care (Basel)       Date:  2008-10-16       Impact factor: 2.860

3.  Clinicopathological study of breast tissue in female-to-male transsexuals.

Authors:  Hajime Kuroda; Kiyoshi Ohnisi; Goi Sakamoto; Shinji Itoyama
Journal:  Surg Today       Date:  2008-11-28       Impact factor: 2.549

4.  Multiple structural and functional abnormalities in the p450 aromatase expressing transgenic male mice are ameliorated by a p450 aromatase inhibitor.

Authors:  Xiangdong Li; Leena Strauss; Sari Mäkelä; Tomi Streng; Ilpo Huhtaniemi; Risto Santti; Matti Poutanen
Journal:  Am J Pathol       Date:  2004-03       Impact factor: 4.307

5.  Presence of exon 5-deleted oestrogen receptor in human breast cancer: functional analysis and clinical significance.

Authors:  A J Desai; Y A Luqmani; J E Walters; R C Coope; B Dagg; J J Gomm; P E Pace; C N Rees; V Thirunavukkarasu; S Shousha; N P Groome; R Coombes; S Ali
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 6.  Breast Imaging of Transgender Individuals: A Review.

Authors:  Emily B Sonnenblick; Ami D Shah; Zil Goldstein; Tamar Reisman
Journal:  Curr Radiol Rep       Date:  2018-01-18

7.  Long-term hormonal therapy resulting in breast cancer in female-to-male transsexual: Case report.

Authors:  Inka Treskova; Ondrej Hes; Vlastimil Bursa
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.